DRNA earnings call for the period ending June 30, 2019.
News & Analysis: Dicerna Pharmaceuticals
DRNA earnings call for the period ending March 31, 2019.
DRNA earnings call for the period ending December 31, 2018.
Investors ponder the biotech's secondary offering.
Investors are happy the biotech ended a lawsuit hanging over its head.
Is this meaningful? Or just another movement?
Find out which health-care stocks ended up as the past week's worst losers.
Investors are craving the risk that's offered by the IPOs of Ultragenyx Pharmaceuticals and Dicerna Pharmaceuticals.
Only if investors continue to accept risk.
Two massive winners in biotech stocks today, including one staggeringly skyrocketing IPO.